DRRX - DURECT Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

DURECT Corporation

10260 Bubb Road
Cupertino, CA 95014
United States

IndustryDrug Manufacturers - Other
Full Time Employees95

Key Executives

Dr. Felix Theeuwes D.Sc., Ph.D.316.76kN/A79
Dr. James E. Brown D.V.M.560.13kN/A60
Mr. Matthew J. Hogan M.B.A.355.26kN/A57
Ms. Judy R. Joice310.85kN/A60
Mr. Michael H. Arenberg J.D., M.B.A.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company’s advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery; and REMOXY ER, an investigational extended release pain relief drug. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd.; Impax Laboratories, Inc.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.

Corporate Governance

DURECT Corporation’s ISS Governance QualityScore as of October 15, 2017 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.